1-(2-(4-溴苯氧基)乙基)吡咯烷 | 1081-73-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(2-(4-溴苯氧基)乙基)吡咯烷
• 中文别名: 1-(4-溴苯氧基)-2-(1-吡咯烷基)乙烷；1-[2-(4-溴苯氧基)乙基]吡咯烷
• 英文名称: 1-[2-(4-bromophenoxy)ethyl]pyrrolidine
• 英文别名: 1-<2-(4-bromophenoxy)ethyl>pyrrolidine；1-(2-(4-Bromophenoxy)ethyl)pyrrolidine
• CAS: 1081-73-8
• 化学式: C₁₂H₁₆BrNO
• mdl: MFCD00003180
• 分子量: 270.169
• InChiKey: YDWKSSWZGXRQET-UHFFFAOYSA-N

物化性质

• 沸点：
  138-140 °C1.2 mm Hg(lit.)
• 密度：
  1.304 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933990090
• 安全说明：
  S26,S37/39
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  常温、避光、存于通风干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-[2-(4-Bromophenoxy)ethyl]pyrrolidine
Synonyms: 1-[2-(4-bromophenoxy)ethyl]pyrrolidine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: N-[2-(4-Bromophenoxy)ethyl]pyrrolidine
CAS number: 1081-73-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H16BrNO
Molecular weight: 270.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-(4-溴苯氧基)乙基)吡咯烷 在 四(三苯基膦)钯 、 三氯化铝 、 sodium carbonate 作用下， 以 乙醇 、 1,2-二氯乙烷 、 苯 为溶剂， 反应 8.0h， 生成 (2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophen-3-yl)-(4-[2-(1-pyrrolidinyl)ethyl]phenyl)ketone
  参考文献：
  名称：

  Diamino Benzo[b]thiophene Derivatives as a Novel Class of Active Site Directed Thrombin Inhibitors. 5. Potency, Efficacy, and Pharmacokinetic Properties of Modified C-3 Side Chain Derivatives

  摘要：

  A systematic investigation of the structure-activity relationships of the C-3 side chain of the screening hit la led to the identification of the potent thrombin inhibitors 23c, 28c, and 31c. Their activities (1240, 903, and 1271 x 10(6) L/mol, respectively) represent 2200- and 2900-fold increases in potency over the starting lead la. This activity enhancement was accomplished with an increase of thrombin selectivity. The in vitro anticoagulant profiles of derivatives 28c and 31c were determined, and they compare favorably with the clinical agent H-R-1-[4aS,-8aS]perhydroisoquinolyl-prolyl-arginyl aldehyde (D-Piq-Pro-Arg-H; 32). The more potent members of this series have been studied in an arterial/venous shunt (AV shunt) model of thrombosis and were found to be efficacious in reducing clot formation. However, their efficacy is currently limited by their rapid and extensive distribution following administration.

  DOI：

  10.1021/jm9903388
• 作为产物：
  描述：

  2-(4-溴苯氧基)乙醇 在 吡啶 、 氯化亚砜 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 20.0h， 生成 1-(2-(4-溴苯氧基)乙基)吡咯烷
  参考文献：
  名称：

  开发高效和立体选择性的碘昔芬制造路线

  摘要：

  对 1-(2-{4-[(E)-1-(4-iodophenyl)-2-phenyl-but-1-enyl]phenoxy}ethyl)pyrrolidine (idoxifene) 的文献途径进行了修改，以应对各种规模-up 问题并提供初始供应。详细描述了一种新的高效、稳健和立体选择性的制造路线。该路线涉及通过非对映选择性合成叔醇 (1RS,2SR)-1-(4-iodophenyl)-2-phenyl-1-[4-(2-pyrrolidin-1-yl-ethoxy)phenyl]butan-1-ol对酮 1-(4-碘苯基)-2-苯基-1-丁酮进行格氏加成，然后进行衍生化和立体选择性顺式消除，从而以优异的收率和几何纯度提供碘昔芬。还描述了使用 McMurry 低价钛偶联反应对碘多昔芬的更直接途径的评估。

  DOI：

  10.1021/op0100394
• 作为试剂：
  描述：

  1-(2-(4-溴苯氧基)乙基)吡咯烷 、 6-甲氧基-2-苯基四氢萘酮 在 1-(2-(4-溴苯氧基)乙基)吡咯烷 作用下， 以54的产率得到1-[2-[4-(3,4-二氢-6-甲氧基-2-苯基-1-萘基)苯氧基]乙基]吡咯烷盐酸盐
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF a-SUBSTITUTED KETONES AND THEIR APPLICATION IN SYNTHESIS OF PHARMACEUTICALLY ACTIVE COMPOUNDS
  [FR] PROCÉDÉ POUR LA PRÉPARATION DE CÉTONES ?-SUBSTITUÉES ET LEUR APPLICATION DANS LA SYNTHÈSE DE COMPOSÉS PHARMACEUTIQUEMENT ACTIFS

  摘要：

  本发明涉及一种新型的一步制备6-甲氧基-2-苯基四氢萘酮的方法，该方法以6-甲氧基四氢萘酮为起始物质，并将其用作合成药用活性化合物的中间体。

  公开号：

  WO2012159981A2

文献信息

• Antithrombotic agents
  申请人：Eli Lilly And Company

  公开号：US06350774B1

  公开（公告）日：2002-02-26

  This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

  这项申请涉及到式(I)的新化合物（及其药用可接受的盐），如本文所定义，用于它们的制备的工艺和中间体，包括式(I)的新化合物的药物配方，以及将式(I)的化合物用作凝血酶抑制剂。
• Antithrombotic diamines
  申请人：Eli Lilly and Company

  公开号：US06025382A1

  公开（公告）日：2000-02-15

  This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.

  该应用涉及将I式中所定义的二胺用作凝血酶抑制剂、凝血抑制剂和血栓栓塞性疾病药剂。它还提供了I式的新化合物，其制备方法和中间体，以及包含这些新化合物的药物配方。
• Discovery of Synthetic<i>Leishmania</i>Inhibitors by Screening of a 2-Arylbenzothiophene Library
  作者：Vivian I. Bonano、Jenicer K. U. Yokoyama-Yasunaka、Danilo C. Miguel、Scott A. Jones、Jeffrey A. Dodge、Silvia R. B. Uliana

  DOI：10.1111/cbdd.12239

  日期：2014.3

  receptor modulators in women and children with leishmaniasis. Three compounds selected from the screening have shown consistent activity against all species and stages of Leishmania in vitro although improvements in selectivity are needed. These compounds represent viable starting points for further optimization as antileishmanial agents.

  他莫昔芬已被证明在体外对利什曼原虫具有活性，并且在鼠模型中对利什曼原虫病的治疗有效。通过筛选雌激素受体调节剂类似物的化合物文库，我们确定了抗疟疾活性所需的主要特征。为了克服他莫昔芬E / Z异构化倾向所带来的困难，我们使用了2-芳基苯并噻吩化合物BTP作为更稳定的替代品。对基于BTP的小型化合物文库的定向筛选导致了针对利什曼原虫的活性化合物。随后在本研究中评估的合成2-芳基苯并噻吩的结构活性数据表明，最佳的抗霉菌药效取决于两个基本侧链的存在。此外，雌激素受体结合所需的主要结构特征 不需要苯酚来抑制寄生虫生长。重要的是，最有活性的苯妥英类苯并噻吩缺乏雌激素受体活性的药效基团，因此解决了在患有利什曼病的妇女和儿童中使用选择性雌激素受体调节剂的不良影响的潜在问题。从筛选中选出的三种化合物在体外对利什曼原虫的所有物种和阶段均显示出一致的活性，尽管还需要提高选择性。这些化合物代表了进一步的优化作为抗
• Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
  申请人：——

  公开号：US20030166644A1

  公开（公告）日：2003-09-04

  Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

  使用化合物抑制激素敏感性脂肪酶，包括这些化合物的药物组合物，使用这些化合物和组合物的治疗方法，以及新化合物。目前的化合物是激素敏感性脂肪酶的抑制剂，可能在治疗和/或预防需要降低激素敏感性脂肪酶活性的医学疾病中有用。
• Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
  申请人：——

  公开号：US20040259915A1

  公开（公告）日：2004-12-23

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新颖的含杂原子四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用，以及它们的制备方法。本发明的化合物在治疗和/或预防与雌激素耗竭相关的疾病中具有用途，例如热潮红、阴道干燥、骨量减少和骨质疏松症；激素敏感性癌症以及乳腺、子宫内膜、宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎，以及作为避孕剂，单独使用或与孕激素或孕激素拮抗剂联合使用。

表征谱图